QV Investors Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 17.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,870 shares of the company’s stock after selling 15,310 shares during the quarter. QV Investors Inc.’s holdings in Johnson & Johnson were worth $11,450,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. GW&K Investment Management LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $35,000. Dark Forest Capital Management LP lifted its position in Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after buying an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $42,000. Kepos Capital LP bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $45,000. Finally, VitalStone Financial LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $52,000. Institutional investors own 67.57% of the company’s stock.
Insider Activity
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,163 shares of company stock worth $7,928,856. Corporate insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $174.48 on Friday. The stock has a fifty day moving average of $161.76 and a 200 day moving average of $161.21. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The firm has a market capitalization of $453.43 billion, a price-to-earnings ratio of 35.32, a PEG ratio of 2.91 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.59 earnings per share. As a group, research analysts expect that Johnson & Johnson will post 10.76 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.73%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How to Invest in the Healthcare Sector
- MarketBeat Week in Review – 7/24 – 7/28
- Canadian Penny Stocks: Can They Make You Rich?
- Can SAIA Continue its Stratospheric Rally?
- What is the Dow Jones Industrial Average (DJIA)?
- Why Markets Are Loving Exxon Mobil, Despite The Earnings Dip
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
